55 results
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:19pm
that the future regulatory and clinical trial programs would not be completed within 12 months from period end and therefore classified contract payments … %
Dividend yield
0%
Expected volatility
100-133%
100%
Remaining term (in years)
1.9–3.5
2.1-3.8
The fair value is classified as level 3 as expected
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:18pm
is uncertain with respect to future years. We believe we were classified as a PFIC during the taxable year ended December 31, 2023. Based on current … in an impairment loss of $64,562. As this valuation technique requires management’s judgement and estimates of the recoverable amount, it is classified
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:15pm
instruments and concluded that the pre-funded warrants should be classified as an equity instrument.
Cash
The Company’s cash equivalents consist of cash …
Expected volatility
Remaining term (in years)
3.8-4.8
The fair value is classified as level 3 as expected volatility is determined using historical
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:12pm
that the future regulatory and clinical trial programs would not be completed within 12 months from period end and therefore classified contract payments … %
Dividend yield
0%
Expected volatility
100-133%
100%
Remaining term (in years)
1.9–3.5
2.1-3.8
The fair value is classified as level 3 as expected
424B3
XRTX
XORTX Therapeutics Inc
13 Jun 24
Prospectus supplement
4:11pm
rules is uncertain with respect to future years. We believe we were classified as a PFIC during the taxable year ended December 31, 2023. Based on current … , it is classified within level 3 of the fair value hierarchy.
The Company will pay the Vendors a royalty, at a rate in the low single digits, based
424B3
xbxzbnxb5qapn1
13 Jun 24
Prospectus supplement
4:10pm
6-K
EX-99.2
p1tmmmmenv dnn
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
6-K
EX-99.1
2apqkbp10bpks9s 0v8e
16 May 24
Condensed Interim Consolidated Financial Statements
6:45pm
424B5
e6jrjnxpjldsfmdhx03
29 Nov 23
Prospectus supplement for primary offering
9:57pm
6-K
EX-99.1
29vsz8v7
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
6-K
EX-99.2
gi6z4387491dtzdm2g
15 Nov 23
Condensed Interim Consolidated Financial Statements
9:30pm
424B3
vsr5frsfcpns
25 Aug 23
Prospectus supplement
6:00am
424B3
xyuxtc9rj4cw8qcvj
25 Aug 23
Prospectus supplement
6:00am
6-K
EX-99.1
1sl468y
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
6-K
EX-99.2
wi19vcygndu yu
15 Aug 23
Condensed Interim Consolidated Financial Statements
6:00am
424B3
4cvnk61
14 Aug 23
Prospectus supplement
4:42pm
424B3
aunpuio0gri
14 Aug 23
Prospectus supplement
4:40pm
POS AM
ujagvjj5k7m4h t5qo02
4 Aug 23
Prospectus update (post-effective amendment)
4:08pm